LYFE Capital
济峰资本
LYFE Capital is a venture capital fund active in China's healthcare and technology sectors, with its deal flow visible in the 2022–2025 window elsewhere's corpus captures. It co-led or joined rounds for antibody-discovery CRO Biointron's nearly RMB 500 million Series B in 2022 , nucleic-drug developer Arnatar's over-$50 million Series A in 2024 , and biotech Zenitar's nearly RMB 400 million Series B+ in 2025 . The fund also backed health-insurance tech firm Stack Data from its 2016 angel round onward . Its investment pattern clusters in life-science services, nucleic-acid therapeutics, and health-tech infrastructure rather than pure drug discovery. elsewhere's corpus does not cover the fund's vintage, AUM, or team background.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
高榕创投·ImmuPharm Raises Nearly RMB 200 Million in Pre-IPO Round Co-Led by Gaorong Ventures, Building Dual Engine in Solid Tumors and In Vivo CAR-T
Bringing long-term survival benefits to cancer patients worldwide.
高榕创投·5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
五源资本·Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
高榕创投·Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
高榕创投·Onto Innovation Completes Over $50 Million Series A Financing to Accelerate Deep Pipeline Expansion in Nucleic Acid Drugs
Focused on drug development based on antisense oligonucleotide technology.
高榕创投·Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
高榕创投·Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
高榕创投·
